Biopharmaceutical company Amgen (AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Revenue rose to $9.1 billion, outpacing the estimated $8.88 billion, up 11% year over year. Free cash flow surged to $4.4 ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Revenue rose to $9.1 billion, outpacing the estimated $8.88 billion, up 11% year over year. Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...